Use of GLP-1 receptor agonists was associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Among US adults without diabetes, the use of GLP-1 RAs increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022.

Experts express alarm that GLP-1 RAs may trigger or worsen eating disorders. But is there any role they might play in binge ...

GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy ...

A new GLP-1 drug, orforglipron, comes in pill form and appears to be roughly as effective as injected drugs like Ozempic.

The rising use of GLP-1 agonists to help manage the obesity epidemic is not only reshaping how consumers taking the ...

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with ...

Both GLP-1 RAs and SGLT2is are associated with a reduced risk for Alzheimer disease and related dementias among people with type 2 diabetes.

So-called GLP-1 supplements, named to echo the class of glucagon-like peptide-1 agonist drugs that includes Wegovy and Zepbound, are likely to be ineffective for weight loss. “If you can buy it ...

Called orforglipron, the results of a new clinical trial announced Thursday by manufacturer Eli Lilly suggest that the pill could be a breakthrough in a class of drugs called GLP-1 agonists ...